eli lilly stock retatrutide The thesis for biopharma stocks may be evolving away from obesity for the first time in four years, says Jared Holz of @MizuhoAmericas, He shares what he thinks investors will consider instead for the Eli Lilly Stock: Next Stop

As retatrutide is not yet approved in the UK, any product currently being marketed or sold as retatrutide outside of a regulated clinical trial has not been assessed for safety or quality by the Medicines and Healthcare products Regulatory Agency (MHRA), and its use carries significant risk

For a detailed head-to-head analysis, see our Retatrutide vs Tirzepatide research guide and the GLP-1 peptides comparison guide

Also noteworthy earlier this month was the publication of a Phase 2 randomized trial in 272 participants without diabetes of orforglipron, an oral GLP-1 agonist, which achieved a 14.7% weight loss (placebo-adjusted 12.3%) at the highest dose With that brief review of the latest trials and drugs, lets turn to clinical outcomes, for which most are taking us back to single agonistGLP-1drugs

Apply the patchto the abdomenand press gentlyfor at least 3seconds